4.3 Article

Development and validation of a cost-utility model for Type1 diabetes mellitus

Journal

DIABETIC MEDICINE
Volume 32, Issue 8, Pages 1023-1035

Publisher

WILEY
DOI: 10.1111/dme.12663

Keywords

-

Funding

  1. Novo Nordisk

Ask authors/readers for more resources

AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available